FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
US ends automatic EAD extensions, affecting many migrant and temporary workers, as DHS aims to restore more robust screening and vetting.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
US ends automatic EAD extensions, affecting many migrant and temporary workers, as DHS aims to restore more robust screening and vetting.